Cargando…

Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials

Androgen deprivation therapy (ADT) has been used in the treatment of metastatic prostate cancer since the first description of its hormonal dependence in 1941. In 2004, docetaxel chemotherapy became the mainstay of treatment in metastatic castration-resistant prostate cancer (mCRPC), following robus...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Soest, Robert J., de Wit, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687286/ https://www.ncbi.nlm.nih.gov/pubmed/26695172 http://dx.doi.org/10.1186/s12916-015-0543-9

Ejemplares similares

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
por: Sharma, Aditya Prakash, et al.
Publicado: (2018)

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
por: Parker, Christopher C, et al.
Publicado: (2018)

Treatment of metastatic prostate cancer after STAMPEDE
por: Wolf, Philipp
Publicado: (2017)

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE
por: Parker, Chris
Publicado: (2018)

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
por: James, Nicholas D, et al.
Publicado: (2022)

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
por: Clarke, N W, et al.
Publicado: (2019)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Las 21 leyes irrefutables del liderazgo
por: Maxwell, John C., 1947-
Publicado: (2006)

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”
por: Ali, Adnan, et al.
Publicado: (2020)

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
por: Puente, Javier, et al.
Publicado: (2020)

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
por: Parker, Chris C., et al.
Publicado: (2022)

Las 21 leyes irrefutables del liderazgo : cuaderno de ejercicios
por: Maxwell, John C., 1947-

Power Relationships: 26 Irrefutable Laws for Building Extraordinary Relationships
por: Sobel, Andrew
Publicado: (2014)

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003
por: Clarke, N.W., et al.
Publicado: (2020)

Las 21 leyes irrefutables del liderazgo : siga estas leyes, y la gente lo seguirá a usted /
por: Maxwell, John C., 1947-
Publicado: (2007)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2016)

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
por: Sydes, M R, et al.
Publicado: (2018)

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
por: Woods, Beth S., et al.
Publicado: (2018)

Hajj Stampede in Mina, 2015: Need for Intervention
por: Salamati, Payman, et al.
Publicado: (2016)

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
por: Clarke, Caroline S., et al.
Publicado: (2022)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
por: Sydes, Matthew R, et al.
Publicado: (2009)

Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems
por: Greasley, Rosa U., et al.
Publicado: (2018)

Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
por: Yuh, Bertram E., et al.
Publicado: (2019)

Psychiatric morbidity in school children who suffered a stampede
por: Bhatia, Manjeet S., et al.
Publicado: (2012)

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
por: James, Nicholas D., et al.
Publicado: (2022)

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
por: Attard, Gerhardt, et al.
Publicado: (2022)

The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
por: Parker, Daniel C., et al.
Publicado: (2020)

Public Health Lesson from Shanghai New Year’s Eve Stampede
por: Huang, Yuee, et al.
Publicado: (2015)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma
por: Carcaboso, Angel M.
Publicado: (2023)

Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform
por: Gilson, C., et al.
Publicado: (2017)

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2012)

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
por: Parry, Marina A., et al.
Publicado: (2023)

Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
por: Lester-Coll, Nataniel H., et al.
Publicado: (2021)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Comparing Two Epidemiologic Surveillance Methods to Assess Underestimation of Human Stampedes in India
por: Ngai, Ka Ming, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_baqc03cjplvk45cv1lkg9d4lqa